Stock Financial Ratios, Dividends, Split History

PRGO / Perrigo Company plc financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)10,804.20
Enterprise Value ($M)13,232.77
Book Value ($M)6,205.40
Book Value / Share44.82
Price / Book1.71
NCAV ($M)-2,533.30
NCAV / Share-18.30
Price / NCAV-4.18
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 143,300,000
Weighted Average Number Of Diluted Shares Outstanding 143,300,000
Common Shares Outstanding 143,397,295
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.34
Return on Assets (ROA)-0.20
Return on Equity (ROE)-0.38
Balance Sheet (mrq) ($M)
Quick Ratio1.48
Current Ratio2.08
Income Statement (mra) ($M)
Sales Revenue Net5,280,600,000.00
Sales Revenue Goods Net5,280,600,000.00
Operating Income-1,999.70
Net Income-4,012.80
Earnings Per Share Diluted-28.01
Earnings Per Share Basic-28.01
Cash Flow Statement (mra) ($M)
Cash From Operations654.90
Cash from Investing-175.00
Cash from Financing-175.00
Identifiers and Descriptors
Central Index Key (CIK)1585364
Related CUSIPS
0G9782210 G97822905 G97822903 714290103 SBGH1M565 G97822953

Split History

Stock splits are used by Perrigo Company plc to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

The 'Joe Papa' Effect Is Arriving At Valeant

2018-06-11 seekingalpha
Investors quite often forget a key valuation component that can't be measured in any exact financial figure: management. Yet it has a significant effect on valuations. (314-2)

Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems

2018-06-09 investorplace
The Canada-based drug company is changing its name on Jul. 1 to Bausch Health Corp. That, along with the new ticker symbol (BHC), is supposed to put the company’s past behind it once and for all, leading to growth and profit for investors. (6-1)

Perrigo Company 2018 Q1 - Results - Earnings Call Slides

2018-05-08 seekingalpha
The following slide deck was published by Perrigo Company in conjunction with their 2018 Q1 earnings call. (1-0)

Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

2018-05-08 zacks
Perrigo Company plc (PRGO - Free Report) reported first-quarter 2018 adjusted earnings of 57 cents per share, which missed the Zacks Consensus Estimate of $1.14 by 50%. The bottom line, however, increased 14% from the year-ago figure of 50 cents. (42-0)

Perrigo Plc (PRGO) Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Good morning. My name is Justin, and I will be your conference operator today. At this time I would like to welcome everyone to the Perrigo First Quarter 2018 Financial Results. Thank you. Mr. Brad Joseph, you may begin your conference. (17-0)

CUSIP: G97822103